X

Trial Profile

Phase III Randomized Study of RFS 2000 (9-Nitro-Camptothecin, 9-NC) [rubitecan] Versus Gemcitabine HCl in Chemonaive Pancreatic Cancer Patients.

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 29 Jan 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rubitecan (Primary) ; Gemcitabine
Indications Adenocarcinoma; Pancreatic cancer
Focus Registrational; Therapeutic Use
Sponsors Astex Pharmaceuticals

Most Recent Events

01 Dec 2011 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently' (last verified June 2007).
15 Sep 2005 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com